REXN Rexahn Pharmaceuticals Inc.

2.85
-0.06  -2%
Previous Close 2.9
Open 2.91
Price To Book 0.97
Market Cap 11,434,456
Shares 4,019,141
Volume 33,237
Short Ratio
Av. Daily Volume 519,804
Stock charts supplied by TradingView

NewsSee all news

  1. Rexahn to Explore Strategic Alternatives

    ROCKVILLE, Md., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 PFS of 5.4 months. ORR 23%. Final data due 2020.
RX-3117 in combination with Abraxane
First-line pancreatic cancer

Latest News

  1. Rexahn to Explore Strategic Alternatives

    ROCKVILLE, Md., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder